Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020

Rhea-AI Summary

Aeglea BioTherapeutics (NASDAQ: AGLE), a clinical-stage biotech firm, announced its participation in the World Orphan Drug Congress USA 2020 from August 24-27, 2020. The company will present on two topics: industry partnerships for patient inclusion and next-generation human enzymes for rare diseases. The first presentation will be moderated by Michael C. Hanley on August 24 at 9:10 a.m. EDT, while the second will be led by CEO Anthony G. Quinn on August 25 at 12:50 p.m. EDT. Aeglea’s lead candidate, pegzilarginase, is in a Phase 3 trial for Arginase 1 Deficiency, having received Rare Pediatric Disease and Breakthrough Therapy Designation.

AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27, 2020.

Presentation Details

Panel Title: Stronger Together: Continuing industry and patient partnerships to ensure inclusion of patient voice along the full continuum of development, from pre-clinical through commercialization
Date/Time: August 24 at 9:10 a.m. EDT
Moderator: Michael C. Hanley, Aeglea’s chief commercial officer

Presentation Title: Next generation human enzymes: Innovative solutions for patients with rare diseases
Date/Time: August 25 at 12:50 p.m. EDT
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer

The company presentation will be available for download on the Presentations & Events section of the Company’s website.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020. Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.

Media Contact:
Kelly Boothe, Ph.D.
Director, Corporate Communications
Aeglea BioTherapeutics
512.399.5458
media@aegleabio.com

Investor Contact:
Joey Perrone
Senior Director, Finance & Investor Relations
Aeglea BioTherapeutics
investors@aegleabio.com

FAQ

What presentations will Aeglea BioTherapeutics give at the World Orphan Drug Congress USA 2020?

Aeglea will give two presentations: one on industry partnerships for patient inclusion on August 24 at 9:10 a.m. EDT, and another on next-generation human enzymes for rare diseases on August 25 at 12:50 p.m. EDT.

When is Aeglea BioTherapeutics participating in the World Orphan Drug Congress?

Aeglea BioTherapeutics will participate in the World Orphan Drug Congress USA 2020 from August 24 to 27, 2020.

What is Aeglea BioTherapeutics known for?

Aeglea BioTherapeutics specializes in developing human enzyme therapeutics for rare and high-burden diseases, with its lead product candidate being pegzilarginase.

What is pegzilarginase and its current status?

Pegzilarginase is Aeglea's lead product candidate, currently in a pivotal Phase 3 trial for treating Arginase 1 Deficiency and has received special designations.

Who is presenting for Aeglea BioTherapeutics at the Congress?

Michael C. Hanley, the chief commercial officer, will moderate the first presentation, and CEO Anthony G. Quinn will present the second topic.